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Objective: Thiosemicarbazones are Schiff based ligands of significant biological importance and their biological relevance has been studied for 
a considerable amount of time period. When the thiosemicarbazones bind with metal ions, they have shown an array of potential anticancer, 
antimicrobial and antioxidant activities etc. They have also found numerous applications in Analytical Chemistry. This present review 
summarizes some of the medicinal benefits of thiosemicarbazone based complexes especially with transition metals.  
Data Sources: The studies cited in the present review were sourced from journals, books and conference proceedings preferentially written 
and published in English. Literature from the past 15 years or so has been included in the article. Papers indexed in known databases such as 
PUBMED, SCOPUS, INDEX COPERNICUS, CHEMICAL AND BIOLOGICAL ABSTRACTS, MEDLINE, EMBASE, EBSCO, DOAJ, and THOMSON REUTERS 
have been reviewed and included.  
Summary of the contents of the article: The study unravels the mechanistic action of these compounds on in vitro living beings viz. cell 
culture as well as animal models. An elaborate review of the available literature on thiosemicarbazones has shown that the modifications in the 
ligand moiety leads to enhancement in its activity and some of the best structural alterations have been cited in the review. Some of the 
potential future applications and uses of the complexes have also been discussed. Structure optimization of the compounds may result in path 
breaking finding of potential anticancer and antimicrobial drugs.  
Conclusion: Latest advances in medicinal inorganic chemistry have given considerable importance to the development of metal based drugs 
with thiosemicabazones. The presence of metal ion in the drug moiety usually mitigates the ill effects of the compounds, this may lead to the 
production of new metal based drugs. The key factors identified for their action has been the inhibition of RR, topo II and t he production of ROS, 
but identification of other probable targets need to be explored. 
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1.0 Introduction 
Cancer causes serious threat to human beings and the death 
rate due to tumours is found to be on rise in the recent years 
[1]. In spite of the decreasing smoking rate and detection in 
the initial stages in the last two decades, the four major 
cancers including lung, bronchus, bronchus, breast and 
colorectum account for 46% of the total deaths [2]. 
According to World Health Organization (WHO) around 7.7 
million people died due to cancer in 2008 and the toll may 
extend to 11 million by the end of 2030 [3]. Cancer is thus 
our society’s major main health concern and is considered as 
the primary aim in connection with medicinal chemistry 
[4].Treating tumour cells which have developed MDR 
(multiple drug resistance) displaying a large spectrum of 
changes in biochemistry and cytogeny such as increased 
expression of p-glycoprotien, enhanced level of glutathione 
related enzymes, down regulation of monooxygenases and 
changed expression of protienkinase C remains a challenge 
[3]. In recent years, researchers have been more focused on 
the discovery of precise target drugs, overseeing the 
generality of cancer cells, such as the uncontrolled 
multiplication caused by the need for more nutrients and 
trace elements [5-6]. Studies have shown that metal 
complexes possess a considerable range of biological and 
chemical properties same when bind with organic moieties 
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[7] so the synthesis of antitumour and antimicrobial drugs by 
forming metal complexes linked with organic ligands has 
been a new strategy [8]. Schiff bases are the class of 
compounds that display a range of biological activities such 
as antifungal, antipyretic, antitumour, antiproliferative and 
antimicrobial [9]. Metal based compounds came into light 
after the success of cisplatin [10-13]. Cisplatin is an 
antitumour compound which is widely used since it was 
discovered in 1960, but some tumor cells have developed 
internal resistance to it, thus the discovery of metal 
complexes with biological activity became the new interest 
for more researches [14]. The general structure of a Schiff 
base is given as Fig. 1 
 
Fig. 1 General structure of Schiff base 
Synthesis of Schiff based ligands is done by condensation 
reaction between primary amine and aldehyde and ketones 
[15] as presented in Fig. 2 and 3 [16]. 
 
 
Fig. 2.Formation of Schiff base by condensation reaction 
 
Fig. 3.Mechanism of formation of Schiff base 
Schiff based thiosemicarbazone and its metal complexes 
shown array of activities such as antitumour, antibacterial 
and antigfungal. Antitumour activity of thiosemicarbazones 
has been found to be analogous to cisplatin [14]. The class 
name “thiosemicarbazone” was given to these compounds 
after the names of the respective aldehyde and ketone. 
Bis(thiosemicarbazones) was thus derived from  di carbonyl 
compounds and two thiosemicarbazone moieties [17]. 
Thiosemicarbazones are synthesized by the condensation 
reaction between aldehyde or ketone with thiosemicarbazide 
[15]. General structure of thiosemicarbazone moiety is 
presented as Fig. 4.  
 
Fig. 4.General Structure of Thiosemicarbazone moiety. R1, R2, 
R3, R4 and R5 may be H, or any organic substituents 
Thiosemicarbazones (TSCs) are a very significant group of 
compounds used for the treatment of several diseases 
including cancer [18-20].Thiosemicarbazones and their 
complexes with metals have wide applications in nuclear 
medicine and analytical chemistry as well [21-23]. 2-
formylpyridine is a TCS whose anticancer activity was 
examined in 1956 [3]. TCS also possess antiviral as well as 
anti-HIV properties [24-26]. The antiviral activity of amino 
acid based thiosemicarbazides has been screened by MIT and 
plaque formation reduction assays and the results stated that 
these compounds inhibited dengue virus infection in vero 
cells. Bz-Trp-TSC is a well-known thiosemicarbazide 
derivative which is used to treat dengue fever [27].There is 
an abrupt change in biological property of the ligands as seen 
in case of coordination of salicylaldehyde semicarbazone and 
thiosemicarbazone with metals which increased its 
antitumour activity and they have a range of applications in 
pharmacological clinical as well as biological areas [29-34]. 
When thiosemicarbazones interact with a charged metal ion, 
due to its polar nature the entry of the metal complex inside 
the cell membrane is facilitated as the hydrophobic part of 
the molecule gets exposed to outside resulting is increased 
activity of the overall compound, Fig. 5. [15]. 
 
Fig.5 Metal ion coordination to a thiosemicarbazone moiety 
induces structural changes in the complex 
This chelating ability of thiosemicarbazones with metal ions 
is a major reason of their anticancer activity [35, 36]. 
Tridentate ligands have better chelating ability as compared 
to bidentate ligands during the formation of stable chelates 
with metals such as Fe, Cu, Mn, Zn and Ga [37]. An extensive 
study has been done on tridentate ligand with NNS structure, 
their ability of chelation and also their pharmacological 
significance [38,39]. Covalent character in the bond between 
metal and ligand increases due to the coupled chromophore 
of quinone-thiosemicarbazone[40]. Owing to their high 
affinity with first transitional row metals they are known as 
potential chelators [41,42]. According to recent studies it has 
been found that the effects produced by central metal as Cu, 
Zn and Ga enhance whereas Fe, Mn and Ni decrease activity 
of the thiosemicarbazone ligand [43-46]. Platinum 
compounds possess antineoplastic potential, but at the same 
time they are toxic, so they cannot be used for clinical 
applications whereas ruthenium complexes are well suited 
for various biological applications. Thota et al. studied a 
variety of ruthenium(II) arene complexes with thiosemi 
carbazone and isonicotinylhydrazone ligands, their biological 
activity and structure activity relationship. The complexes 
possessed anticancer potential. The cytotoxic activity of 
these complexes has been checked against Molt 4/C8, L1210, 
CEM, HL60 and BEL7402 cell lines and the compounds 
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displayed significant inhibitory activity against many cell 
lines with IC50 in the micro molar range [47]. A range of 
bisthiosemicarbazone copper complexes have antitumour 
properties [48-50]. Copper complexes also have a limitation 
in terms of poor solubility and high toxicity in vivo [51,52]. 
Numerous attempts have been to modify thiosemicarbazone 
complexes in order to improve hydrophobicity and reduce 
its toxicity [53]. 
1.1 Derivatives of thiosemicarbazone:  
Anticancer activity has been observed against HCT116 
tumour cells in novel quinolene derivatives which are 
considered as iron chelators and structurally bind with the 
active moieties of identified quinoline and thiosemi-
carbazonebio effectors. Palladium complex of 
phenylanthrenequinone thiosemicarbazone has been 
synthesized and found to have antiproliferative properties 
against breast cancer cells [15]. Chandra et al. synthesized 
novel macrocyclic ligands with Mn, Co, Ni, Pd and Cr in +2 
oxidation state as M(L)Cl2 and Pt(L) viz 1,3,4,8,9,11-hexaza-
5,7,12,14-tetraphenyl-2,10-dithiocyclotetradecane(L). 
Characterization of the complexes was done using  elemental 
analysis, molar conductance, magnetic susceptibility, mass, 
H1 NMR,IR,UV-visible and spectral studies and their 
screening was done in lab and they were found to possess 
activity against a class of bacteria and plant pathogenic fungi 
[54]. A group of MIZCA-TSC ligands were synthesized by the 
reaction of MIZCA(methyl-imidazole-2-carboxaldehyde) with 
common methyl substituted thiosemicarbazone and the NMR 
characterization confirmed the proposed structure of the 
ligands. These ligands formed chelates with Cu(II) and Pd (II) 
salts and the Pd (II) complexes were found to possess 
maximum antiproliferative activity[ 55]. Milligan et al. 
synthesized novel compounds through the reaction of 2-
Acetyl-6-bromopyridine (ABrPy) with thiosemicarbazides to 
form a range of new 2-acetyl-6-bromopyridine 
thiosemicarbazone (ABrPy-TSC) ligands which were 
recrystallized and analyzed via 1H NMR and 13CNMR 
spectroscopy. They formed metal complexes of the ligands 
with Cu(II) and their MIC (minimum inhibitory 
concentration) studies  were performed  to confirm the anti-
microbial properties of each TSC compound and it was found 
that the Cu metal complexes of the ligands exhibited 
potential anti-proliferation activities[56]. J.R. Pawar et al.  
synthesized heterocyclic base adducts of cobalt (III) 
complexes by the reaction of cobalt (II) chloride with 5-
chloro-2-hydroxy acetophenonethiosemicarbazone and N(4) 
Me-thiosemicarbazone with heterocyclic base like 2,2'-
bipyridine (bipy), 1,10-phenanthroline (Phen) and 8-amino 
quinolone, which were characterized by 13C, 1H NMR as well 
as IR, electronic spectra. The octahedral geometry for six 
coordinate complexes was confirmed by magnetic and 
spectroscopic data. The thiosemicarbazones and its 
cobalt(III) complexes displayed  inhibitory activity against 
Pseudomonas putida, Escherichia coli, Aspergillusniger and 
Candida albicans. [57]. 2-butanone thiosemicarbazone and 
their 11 complexes of the type ML2X2, ML2X', where M = 
Cu(II), Cd(II), Co(II), Zn(II), Hg(II); L=2-butanone 
thiosemicarbazone; X = Cl-, NO3- or CH3COO-, X'= SO42- have 
been synthesized and characterized using infra-red and 
ultra-violet spectroscopy which confirmed the bidentate 
nature of the ligand utilizing thionic sulfur and the 
azomethine nitrogen atom for co-ordination to the central 
metal atom and  some of the complexes displayed activity 
against Gram positive bacteria Staphylococcus aureus, 
Staphylococcus epidermidis and Gram negative bacteria 
Escherichia coli and Pseudomonas aeruginosa. [58]. 
Heterocyclic thiosemicarbazones have also been studied for 
their inhibitory action against gliomas which are tumours 
present in human central nervous system [59]. (N)-
heterocyclic thiosemicarbazones resulting from 2-formyl, 2-
acetyl, and 2-benzoylpyridine have also been investigated for 
their activity against gliomas [60]. Complexes of transition 
metals with the condensation products of 3-acetylpyridine 
(3-Acpy) with hydrazines and thiosemicarbazide have been 
synthesized and characterized [61]. Complexes of derivatives 
of 3-Acpy with semicarbazide, semioxamazide and 
thiosemicarbazide [62] have also been investigated in which 
it was found that 3-Acpy derivative coordinated in a 
monodentate manner via carbonyl oxygen or via pyridine 
nitrogen [63]. Mariasa et al. synthesized pyridoxal-
thiosemicarbazone copper(II) and cobalt(III) complexes with 
nitroprusside  and  investigated antileukemic activity of 
three of these complexes against U937 and CEM [64].A series 
of new nopinone-based thiosemicarbazone derivatives have 
been designed and synthesized by Yunyun et al. as potential 
antitumour agents. In the in vitro antitumour activity, most 
derivatives showed significant cytotoxic activity against 
MDA-MB-231, SMMC-7721 and Hela cell lines. Some of the 
compounds exhibited good anticancer activity against the 
tested cancer cell lines with the IC50 values 2.79 ± 0.38, 2.64 
± 0.17 and 3.64 ± 0.13 M, respectively. Furthermore, the cell 
cycle analysis indicated that the compounds caused cell cycle 
arrest of MDA-MB-231 cells at G2/M phase. The Annexin V-
FITC/7-AAD dual staining assay also showed that some 
compounds induced early apoptosis of MDA-MB-231 cells 
[65]. Two new Cu(II) mixed-ligand complexes with 
octadentate N,N',N'',N'''-tetrakis(2-pyridylmethyl)-1,4,8,11 
tetraazacyclotetradecane (tpmc) and pentadentate ligands 
2.6-diacetylpyridine bis(semicarbazone) (DAPsc2) or 2,6-
diacetylpyridine bis(thiosemicarbazone) (DAPtsc2) have 
been synthesized by Tanaskovic. The general formulae 
[Cu4DAPsc2(tpmc)2] (ClO4)8·5CH3COCH3·H2O and 
[Cu2DAPtsc2(tpmc)](ClO4)4 ·7EtOH were proposed from 
elemental analyses and conductometric measurements. For 
the dinuclear complex, an exo-coordination of Cu(II) with 
four nitrogens from tpmc and μ-bonded DAPtsc2 through 
sulfurs and probably terminal hydrazinic (azomethine) 
nitrogens was assumed. For the tetranuclear complex, one 
DAPsc2 bridged two [Cu2tpmc]4+ units using oxygens and 
terminal hydrazinicnitrogens as ligators. The antibacterial 
activity of the complexes was also established [66]. A zinc 
complex of the 2-benzoylpyridine thiosemicarbazone(Hbpt) 
viz. Zn(bpt)2·DMF, has been synthesized and characterized 
by elemental analysis, IR spectra and single crystal X-ray 
diffraction by Li et al. The molecular structure showed that 
Zn(II) cation bonded to two perpendicular bpt ligand in a 
distorted octahedral geometry through two sulfur and four 
nitrogen atoms. The crystal contained a disordered DMF 
solvate molecule. Adjacent molecules were found to be 
interconnected by means of hydrogen bonding generating a 
one dimensional chain structure. The cytotoxic activity 
dimension indicated that the complex exhibited higher 
anticancer activity against lung cancer A549 cell lines than 
the free ligand [67]. Twelve cobalt(II) and nickel(II) 
complexes, [M(L)(H2O)2(Y)] (M =Co(II) or Ni(II); Y= Cl-, Br- or 
NO3-) containing the Schiff-bases 4-hydroxycoumarin-3-
carbaldehyde semicarbazone and thiosemicarbazone, HL1 
and HL2 respectively were synthesized. The metal complexes 
were checked for their antifungal and antibacterial activities 
on different species of pathogenic fungi and bacteria [68]. 
Thiosemicarbazones of citronellal and menthone and their 
nickel(II), copper(II) complexes were synthesized and 
characterized by PhanThi Hong using IR,UV-VIS, MS and 
NMR spectroscopies. The results indicated the formation of 
1:2 metal to ligand complexes with empirical formulas [CuL2] 
and [NiL2] (HL:thiosemicarbazone). The Cu(II) and Ni(II) 
complexes were four coordinate and square planar in 
geometry in which the ligands behaved as bidentate 
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chelating agents in the uni-negatively charged form. The 
biological activity of thiosemicarbazones and its complexes 
against bacteria, fungi and cancer cell lines was also assessed 
[69]. Hitesh et. al. synthesized a series of thiosemicarbazones 
of 1-(5-chloro-1H-benzimidazol-2-yl)ethanone and studied 
theirin vitroantitumor activity against 60 human cell lines 
derived from nine clinically isolated cancer types viz. 
Leukemia, lung, colon, CNS, melanoma, ovarian, renal, 
prostate and breast, according to a standard protocol 
established at the National Cancer Institute, Bethesda, MD, 
USA [70]. Some of the important derivatives of 
thiosmeicarbazones along with their biological activity have 
been summarized in table 1. 
 
Table 1.Some recent important derivatives of thiosemicarbazones and their activity spectru 
S.No. Year Derivative Coordinating  
metal 
Activity tested Ref. 
1 2018 (E)-N-ethyl-2-[1-(thiazol-2-yl)-propylidene] 
hydrazinecarbothioamide. 
(E)-N-tert-butyl-2-[1-(thiazol-2-yl)-propylidene 
]hydrazinecarbothioamide 
Cu(II) Anticancer 71 
2 2017 C18H20N6O6 Cu(II) Anti-microbial 72 
3 2017 Izatiton-izatinthiosemicarbazone derivative - Antiviral, 
antitumour 
73 
4 2016 di-2-pyridylketone 4,4-dimethyl- 
3-thiosemicarbazone (Dp44mT) 
- Anticancer 74 
5 2016 3-acetyl coumarin 
thiosemicarbazone 
- Neuroprotective 75 
6 2016 Thiosemicarbazone and Chloroethanol Cu(II) Antibacterial, 
Antifungal, 
Anticancer 
76 
7 2016 Benzoin Thiosemicarbazone Co(II), Ni(II) Antibacterial 77 
 
, MeleJesmin and Shaikh Mohammad Mohsin 
8 2016 Benzaldehydesemicarbazone, 
Benzaldehyde thiosemicarbazone 
As(III) Antimicrobial 78 
9 2016 8-ethyl-2 hydroxytricyclo(7.3.1.02,7)tridecan-13-one-thio-
semicarbazone 
Cu(II),Pd(II), 
Pt(II) 
Antimicrobial, 
Antiproliferative 
79 
10 2015 Acetylcyclohexanthiosemicarbazone 
(ACHTSC) 
 Antibacterial 80 
11 2015 Acetyl acetone semicarbazone, 
acetyl acetone thiosemicarbazone, benzoyl acetone 
semicarbazone, benzoyl acetone 
thiosemicarbazone, glyoxalsemicarbazoneglyoxal 
thiosemicarbazone. 
Sn(II) Antimicrobial 81 
12 2015 5-allyl-2-hydroxy-3-methoxybenzaldehyde-4-
thiosemicarbazone [H2L,1], [MeSnCl(L)] (2), [BuSnCl(L)] (3) 
[PhSnCl(L)] (4) [Me2Sn(L)] (5) 
Sn(IV) Antibacterial 82 
13 2015 1) 2–methoxybenzaldehyde 
semicarbazone/ thiosemicarbazone (mbsc, mbtsc) 
22–bromobenzaldehydesemicarbazone/ 
thiosemicarbazone (bbsc, bbtsc) 
Cu(II)  83 
14 2015 Gallium(III)thiosemicarbarbazone Ga (III) Antiproliferative 84 
15 2015 1)6-(3-thienyl) pyridine-2-carboxaldehyde-4N-ethyl 
thiosemicarbazone 
2)6-(3-thienyl) pyridine-2-carboxaldehyde-4N-phenyl 
thiosemicarbazone 
Cu(II) Antibacterial, 
Antifungal, 
Antioxidant 
85 
16 2014 Quercetinthio semicarbozone(QTSC) Cu(II) Antioxidant, 
Antitumor,  
Anticancer 
 
86 
17 2014 1-methylpyrazole-3-aldehyde-4-(2-pyridyl) thiosemicarbazone Cu(II) Antimicrobial  87 
18 2014 Acetylpyrazine-thiosemicarbazone Cu(II), Pd(II), 
Pt(II) 
Antimicrobial 88 
19 2014 2(E)-2-[1-(4-
pyridinyl)ethylidene]hydrazinecarbothioammidehydrochloride 
Cu(I) Anticancer 89 
20 2013 1-TSCND (2-hydroxy-1,4-naphthalenedione-1-
thiosemicarbazone) 
Ni(II) Anticancer  90 
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21 2013 1)4-phenyl-1-(acetone)-thiosemicarbazone 
2)4-phenyl-1-(2'- 
chloro-benzaldehyde)-thiosemicarbazone 
3)4-phenyl-1-(3'-hydroxy-benzaldehyde)-thiosemicarbazone 
4)4-phenyl-1-(2'-naphthaldehyde)-thiosemicarbazone 
5)4-phenyl-1-(1'-nitro-2'-naphthaldehyde)-thiosemicarbazone, 
 
Pd(II) Antiproliferative, 
Antitumor 
91 
22 2013 SalicylaldehydeThiosemicarbazone Fe(II), Co(II) Antimicrobial 
 
92 
23 2012 4-R-benzaldehyde thiosemicarbazones (denoted as 
H2L-R, where H2 stands for the two dissociable protons and R 
(R = -OCH3, CH3, H, Cl- and NO2-) 
Pt (II) Antitumor 93 
24 2011 4-(2-pyridyl)-3-thiosemicarbazide with phenyl isothiocyanate, 
benzoyl isothiocyanate, phenyl isocyanate and 4-pyridyl 
isothiocyanate. The products were N1-phenyl-N2-(pyridin-2-
yl) hydrazine-1,2-bis (carbothioamide) (H2PPS), N-phenyl -2-
(pyridine-2-ylcarbamothioyl) hydrazine carboxamide 
(H2PBO), 1-(amino (thioformyl)-N-phenylformyl)-4-(pyridine-
2-yl)thiosemicarbazide (H2APO) and 1-(aminoN-(pyridine-3-
yl)methanethio)-4-(pyridine-yl)thiosemicarbazide (H2PPY) 
respectively. 
 Antiproliferative,  
Anticancer 
 
94 
25 2011 Chalcone thiosemicarbazide derivatives  Anticancer, 
Antiproliferative 
 
95 
26 2011 Thiosemicarbazide derivatives of 4-(3-(Benzofuran-2-yl)-1-
phenyl-1H-pyrazol-4-yl)-2-hydrazinyl-1,6-dihydro-6-
oxopyrimidine-5-carbonitrile 
 Antitumor  
96 
27 2011 2-phenylcarbonylquinoxaline thiosemicarbazone Co(II), Ni(II), 
Cu(II) 
Antibacterial, 
Antifungal 
97 
28 2010 Triapine (3-aminopyridine-2-carbaldehyde 
thiosemicarbazone) 
Cu(II), 
Zn(II),Fe (II) 
Antitumor 98 
29 2010 6-hydroxy chromone-3-carbaldehyde thiosemicarbazone Ni (II) Anticancer 99 
30 2010 bis(phenylthiosemicarbazone) Cu(II), Ni(II) Antioxidant, 
Antibacterial 
100 
31 2009 2-pyridinecarboxaldehyde thiosemicarbazone Mn(II), Co(II) Antibacterial 101 
32 2008 2-acetylpyridine 
thiosemicarbazones and aniline 
Co(II), Ni(II), 
Cu(II) 
Antimicrobial 102 
 
33 2007 N(4)-o-, N(4)-m- and N(4)-p-tolylthiosemicarbazones Cu(II) Antimicrobial 103 
34 2007 6-methyl-2-pyridylformamide semicarbazone and 6-methyl-2-
pyridylformamide thiosemicarbazone 
Co(II), Ni(II) 
Cu(II) 
Antifungal 104 
35 2005 4-aminoantipyrine thiosemicarbazone Co(II), Ni(II) Antibacterial,  
Antifungal 
105 
36 2001 5-methyl 2-furfural thiosemicarbazone 
 
Ni(II) Antifungal 106 
 
2.0 Mechanism of action of thiosemicarbazones  
Thiosemicarbazones work by the following mechanisms- 
2.1.Inhibition of 
RibonucleosideDiphosphateReductase(RR) 
The conversion of ribonucleotide to deoxyribonucleotide 
which forms DNA in all the cell types is done by 
Ribonucleotide reductase (RR) [107]. The total rate of DNA 
synthesis is regulated by RR such that the DNA to cell mass 
can be maintained at a constant rate ratio during DNA 
repairing and cell multiplication [108]. The anticancer 
activity and ribonucleotidereductase inhibitory activity of a 
thiosemcarbazide derivative 3AP has been advanced to 
clinical trials [109,110]. Antiproliferative activity on different 
cancer cells is found in thiosemicarbazoness a NNS-
thiodentate ligand through chelation[111] and TCS inhibits 
an iron dependent enzyme ribonucleotidereductase[112]. 
The activity of this enzyme is initiated by tyrosyl radical and 
its inhibition leads to the death of the cell (apoptosis) due to 
the blockage in the S phase of the cell cycle [15]. QSAR 
analysis of 21 compounds which are thiosemicarbazone 
derivative showing RNR inhibitory activity was 
performed.The inhibitory concentration (IC50) in the IM 
range was reported for 13 of them. The inhibitory 
concentration of those compounds was converted into -log 
IC50 before being correlated with structural features [113]. 
Due to the tetradentate nature the 
Pyrazinecarboxaldehydethiosemicarbazones and 1-
formylisoquinolene thiosemicarbazone which are alpha (N) 
heterocyclic thiosemicarbazonethey are better chelators due 
to their tridentate nature [114]. 5-HP(5 hydroxyl 2-
formylpyridine) is one of the earliest known inhibitors of RR 
that showed high activity in animals but its activity 
decreased in humans due to rapid excretion. This molecule 
acts on tyrosyl radical and destroys it[115]. In 1960s certain 
formylpyridylthiosemicarbazones were discovered to be 
powerful inhibitor of RR [116,117] and RR maintains the 
process of DNA synthesis and repair. Triapine also causes 
ribonucleotide reduction and is the most investigated ligand 
[118-119] Drugs belonging to this group class have 
undergone phase I and II trials as an anticancer agent 
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[120,123,126-131].They exhibited promising properties in 
vivo but also caused some side effects which including 
diarrhea, nausea, neutropenia, thrombocytopenia, 
methemoglobinemia[132-133].A considerable amount of 
study on the biological, chemical and electrochemical 
properties of triapine and substituted variants and 
complexes with Fe and Ga has been performed by 
Kolinowski et al. [133]. N heterocyclic tridentate 
thiosemicarbazone play a significant role as iron chelator 
and are used for biomedical purposes [134]. Gallium 
complexes of triapine displayed an increase in toxicity than 
the iron complexes and RR inhibition was found to be 
responsible for cytotoxicity. The Fe(II)bis (triapine)complex 
has also been identified as a more effective RR inhibitor than 
the Fe(III) species and was found to attach itself to the 
tyrosyl radical present in the ribonucleotide reductase 
subunit [135]. The cellular disruption of triapine and its zinc 
complex was found out by confocal fluorescence microscopy 
displaying dispersion in the cytosol [136] which was found 
to be consistent with RR inhibition. The chelation with iron 
could play an important role by reducing the availability of 
Fe for RR and thereby reducing the RR activity which was 
measured by EPR of the quenching of the tyrosine radical 
[137]. It is evident that the Fe thiosemicarbazone complexes 
generate radical species on reduction and can carry out 
Fenton type of reaction to generate hydroxyl mediated by the 
presence of oxygen. The ROS can also degrade the DNA 
providing an additional mechanism for cytotoxicity. The 
reduced RR activity for analogues of Ga would stimulate the 
Fe based radical formation but it doesn’t explain the greater 
cytotoxicity of Ga complexes than Fe complexes [138] 
2.2 Inhibition of Topoisomerase II and DNA interactions 
Topoisomerase is an enzyme found in eukaryotic cells that 
causes decatenation of DNA and is necessary for DNA  
replication. It also prevents supercoiling during replication 
[139,140]. Topoisomerase II plays important function in cell 
multiplication and is richly found in rapidly proliferating 
cancer cells. TCS are powerful antitumour agents that inhibit 
topoisomerase II activity. Relationship between in vitro and 
in vivo performance of 64Cu-labelledthiosemicarbazide 
complexes and the expression of Topo-II activity has been 
investigated [141]. Four 4N-azobicyclo [3.2.2] nonane 
thiosemicarbazideligands were prepared and radiolabelled 
with 64Cu which leads to the formation of lipophilic cations. 
Of the four ligands investigated in the study three have been 
found to possess better growth inhibition property  when 
compared with non-radioactive copper with IC50 value of 
0.004μmol/l in HT29 cells. A wide range of tridentate TSCs 
with nitrogen based heterocycles have been tested.A ligand 
bearing aquinoline group has been identified to have 
particularly great cytotoxicity and ability to checkTopo-II 
activity. The mechanism of inhibition recommended that the 
blockage [142]. A succeeding paper has examined the Topo-
II inhibition by Cu complexesof same ligand types and has 
revealed them to be effective inhibitors of Topo-II [143]. Cu-
thiosemicarbazonecomplexes ha possess superior growth 
inhibitory activity than the uncomplexed ligand and have 
lesser IC50values against tumor cells than the reported Topo-
II inhibitors [144]. Anticancer property of 1,2 
naphthoquinone-2-thiosemicarbazone and its metal 
complexes of Cu (II), Pd (II) and Ni (II) has been checked 
against breast cancer(MCF-7) cell line showing their 
potential anticancer activity. The Ni complex has been highly 
effective based onIC50 values [145]. Further investigation of 
the ligands and complexes has shown that they can only even 
out the single-strand DNA. The metal complexes of these 
ligands exhibit an antagonizing effect on Topo-II activity, as 
compared to the free ligands. In another study, Cu(II) 
complexes of 4-hydroxy-3-methyl-1,2 naphthoquinone-1-
thiosemicarbazone have shown chief toxicity in the cell 
related to those of Fe(II), Ni(II), Pd(II) and Pt(II) metal 
complexes with the same ligand [146]. The binding doesn’t 
allow the proper functioning of the protein complex during 
DNA and its interaction. Further studies on mechanism of 
action have shown that metal complexes could alleviate the 
cleavable complex formed by DNA and Topo-II. Studies have 
shown that iron and copper complexes perform better cell 
destruction as well as in the prevention of DNA synthesis 
than the uncomplexed thiosemicarbazone [147]. 5-hydroxy-
2-formyl thiosemicarbazone has been revealed to create 
lesions in DNA [148]. It has been proven that a tridentate 
nature and a high formation constant is a qualified for 
increased activity by comparing the activity of pyrazine 
thiosemicarbazone derivatives and an analog derived from 
acetophenone. These compounds alter the iron hemostasis 
by preventing the iron exchange from the serum transferrin. 
In a very current study, Topo-IIα inhibition and 
antiproliferative activity of α-
heterocyclicthiosemicarbazones and their analogous 
copper(II) complexes has been found. Cu 
(II)(thiosemicarbazonato)Cl complexes has been shown to 
catalytically inhibit Topo-IIα at concentrations 0.3-7.2μM 
The copper complexes have also shown inhibitory action 
towards the proliferation of breast cancer cells (SK-BR-3) 
expressing high levels of Topo-IIα at lower concentrations 
than breast cancer cells (MCF-7) showing lower levels of the 
enzyme [149]. Copper complex of acetylpyridinemethyl 
thiosemicarbazone inhibits Topo-IIα enzyme and  the 
palladium(II) and platinum(II) complexes of the same ligand 
also inhibits the enzyme due to the same structural geometry 
(square planar around the metal), a series of acetylpyridine 
thiosemicarbazone ligands, and their Cu(II) and Pd(II) metal 
complexes have been synthesized and characterized by NMR 
and the results proved that the Cu II complexes have better 
antiproliferative property than Pd II complexes[150].  
2.3. Reactive Oxygen Species Generation 
Redox metal complexes can operate as ROS generators. Since 
most thiosemicarbazone complexes possess redox metal 
ions, they potentially activate O2 and produce OH- radicals 
[15]. [Cu(L)2(pz)](ClO4) and {[Cu(L)2(dca)](ClO4)} complexes 
where L=2-formylpyridine TSC, pz=pyrazine and 
dca=dicyanamide have been tested for their biological 
activity on DNA. The oxidative breaking of DNA has been 
investigated in the presence of 3-mercaptopropionic acid as 
reducing agent by the process of gel electrophoresis using 
supercoiled pUC18 and these complexes have been found to 
produce single and double strand breaks in DNA [151].  
Copper is a vital micronutrient and has significant biological 
functions such as cellular trafficking, redox regulation [152-
153] and angiogenesis modulation etc. [154-155]. Cu (II) 
complex-mediated cytotoxicity studies are on the rise [156-
157]. Four novel thiosemicarbazone metal complexes, 
[Cu(Am4M)(OAc)]·H2O (1), [Zn(HAm4M)Cl2] (2), 
[Zn2(Am4M)2Br2] (3) and [Zn2(Am4M)2(OAc)2]·2MeOH (4) 
[HAm4M=(Z)-2 (amino(pyridin-2-yl) methylene)-N-
methylhydrazinecarbothioamide], have been investigated 
and tested against HepG-2 cell.  IC50 value (11.2±0.9 μM) of 
complex 1 against HepG-2 cells has been found to be nearly 
0.5 fold of that against human hepatic cell lines LO2, showing 
a reduction in the side effects to liver cells. It has been seen 
that to display a stronger inhibition on the viability of HepG-
2 cells than cis-platin (IC50=25±3.1μM), suggesting complex-
1 might be a good anticancer agent. Copper(II) is very 
receptive to electron transfer, whereas zinc(II) is difficult to 
participate in redox reaction because of the non-availability 
of variable valency. Fluorescence microscopy inspection and 
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flow cytometry analysis has exposed that complex-1 cannot 
repress HepG-2 cell viability and encourage systematic cell 
death. Some indexes, such as DNA cleavage, ROS production, 
comet assay and cell cycle analysis have shown that the 
antitumor mechanism of complex 1 on HepG-2 cells might be 
via ROS-triggered apoptosis pathway [158]. Complexes 1-4 
have been found to display different coordination geometries 
even in parallel synthetic conditions, which is accredited to 
the nature of metal ion and its  ionic radius, coordination 
numbers, different counter anions (Cl−, Br− and OAc−) etc. 
[15]. Non-Hodgkin’s lymphoma and bladder cancer are 
treated by using gallium nitrate. [158-159]. Lymphomas are 
disrupted by Gallium nitrate by increasing intracellular 
reactive oxygen specie and up-regulating cyclin D1 [160]. 
Alkyl/aryl-1,2naphthoquinonesthiosemicarbazones were 
synthesized and characterized. The crystal structure of the 
free ligands viz. 4-Pyrrolidine-1-yl-[1,2] naphthaquinone 
thiosemicarbazone  copper complexes showed their E' 
conformation which were checked for their DNA cleaving 
activities in case of circular double stranded plasmid DNA 
pBR322 in the presensence of oxygen. All Cu conjugates 
showed more pronounced interaction with DNA  presence of 
the oxidant [161]. 
2.4. Inhibition of tyrosinase 
For the process of melanognesis inhibition tyrosinase is 
chosen as a target since it catalyzes the rate-limiting step of 
melanin production tyrosinase and is used in the production 
of anti-hyperpigmentation agents. Thiosemicarbazones have 
been found to inhibit the action of tyrosinase [162].  
Fig. 6. Structure-activity relationship of thiosemicarbazones 
towards mushroom tyrosinase [162] 
Since tyrosinase contains two copper atoms in its moiety, 
thiosemicarbazones usually containing S and N atoms as 
donors bind with the copper atoms.  Sulfur atom particularly 
shows the ability to chelate copper ions in the active site of 
tyrosinase. Thiosemicarbazones and thiosemicarbazide are 
different only by one proton. There are few possibilities of 
proton substitution and a lot of compounds with at least one 
substitution of proton have been found to inhibit tyrosinase 
[163-164]. Benzaldehyde thiosemicarbazone has been to be 
a few times more effective in the inhibition of tyrosinase 
[165-166]. Xie et al. have reported the effect of thiophene, 
furan and pyrrole rings on the inhibitory potential of the 
synthesized compounds [167]. 
Yi  
 A group of mono-ligand trisubstituted benzaldehvde 
thiosemicarbazone derivatives containing hydroxy or 
methoxy groups on the benzene ring was synthesized by Yi 
et al. and the substitution at the 4th position of phenyl ring 
was found most effective for the inhibition of tyrosinase 
enzyme [168].The interaction kinetics of 4 hydroxy and 4 
methoxy benzaldehyde thiosemicarbazones with tyrosinase 
was studied by Chen et al. [169]. Inhibition kinetics for 2-
chlorobenzaldehyde thiosemicarbazone (A) and 4-
chlorobenzaldehyde thiosemicarbazone (b) showed 
reversible inhibition when it was investigated by Lie et al. 
[170]. For 2-chlorobenzaldehyde thiosemicarbazone (A) IC50 
was 15.4 and 1.22μM for mono- and diphenolase activity of 
the enzyme, respectively and for 4-chlorobenzaldehyde 
thiosemicarbazone (B) it was 6.7 and 1.82 μM respectively. A 
was noncompetitive inhibitor with Ki value of 1.20μM and B 
showed mixed-type inhibition with Ki and Kis of 1.25 and 
2.49μM, respectively. For monophenolase activity, A and B 
(Fig.7) lowered reaction rate but did not control the lag time. 
Fig. 7. Structures of 2-chlorobenzaldehyde 
thiosemicarbazone(A),4 –chlorobenzalde 
hydethiosemicarbazone(B) 
Zhu et al. synthesized the derivative of cinnamaldehyde and 
thiosemicarbazide and proved it as a reversible mixed-typed 
inhibitor of diphenolase tyrosinase activity. It’s Ki and Kis 
values were 4.45 and 8.85μM, respectively. For 
monophenolase activity, inhibitor not only lowered the 
steady-state rate but also lengthened the lag time [171]. The 
inhibition potential of two 4-dimethylaminobenzaldehyde 
thiosemicarbazone derivatives was studied by Yang et al. and 
the substitution of proton from thiosemicarbazide terminal 
group with phenyl moiety. In this case IC50 was calculated for 
both mono and diphenolasetyrosinase activity and it was 
1.54 and 2.02μM for 4-dimethylbenzaldehyde 
thiosemicarbazone and 1.78 and 0.80μM for 4-dimethyl 
aminobenzaldehyde-N-phenyl-thiosemicarbazone 
respectively. Both compounds showed reversible mode of 
inhibition. Substitution of proton in position R5 with phenyl 
group changed the inhibitory action of 4-dimethylamino 
benzaldehyde-N-phenyl-thiosemicarbazone, as it inhibited 
tyrosinase in to non-competitive type, enhancing inhibitory 
potency (Ki 0.77μM).Both compounds inhibited tyrosinase 
activity but slightly prolonged the lag time [172]. 
2.5. Multidrug resistance protein (MDR1) inhibition 
Multidrug resistance is a major hurdle and clinical challenge, 
when it comes to development of anti-cancer drugs. Some 
tumour cells develop particular multidrug resistance (MDR), 
which makes the cells resistant to other classes of anticancer 
drugs to which the tumour cells have not been treated before 
[173]. Pd complexes with phenanthrenequinone 
thiosemicarbazone have been investigated for their anti- 
proliferative activity in the breast tumour cells and normal 
cells. The results revealed that the complex possessed potent 
anti neoplastic property having selective activity against 
tumour cells and found to be significant in curing breast 
tumour cells that has developed resistance to these drugs 
[174]. 
2.6. Other mechanisms 
It has also been seen that substitution on terminal nitrogen 
increases the overall activity of the complex. 2-formyl- and 2-
acetylthiosemicarbazone and their metal complexes with 
zinc have been tested against MCF7, T24 and L-929 [175]. 
Later acetyl derivative was modified by adding an ethyl 
group on terminal nitrogen and its Pt and Pd complexes were 
prepared with the formula, [ML2], M=Pd, Pt. The complexes 
showed activity towards cis-platin resistant tumour cell lines 
and role of metal was not found to be significant [176]. In 
another ssimilar study 8-hydroxy quinolone-2-
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carboxaldehyde thiosemicarbazone and its 4,4-dimethyl 
derivative along with their Cu (II) complexes. The terminal 
amino substituted complex showed greater anticancer 
activity than the unsubstituted complex. The activity was 
checked on SK-N-DZ (a cisplatin resistant neuroblastoma cell 
lines). Improved expression of p53 protein was detected in 
the SK-N-DZ cells treated with the non- methylated complex 
suggesting that apoptosis was caused by DNA breakage 
[177]. Quinoline-2-carboxaldehyde thiosemicarbazone 
derivatives and their Cu (II) complexes have been found to 
generate apoptosis by inhibiting proteasome-ubiquitin 
pathway and not pass oxidative stress [178]. This shows an 
additional pathway of action. A zinc complex of 2-
benzoylpyridine thiosemicarbazone (Hbpt), Zn(bpt)2·DMF, 
has been synthesized and characterized by elemental 
analysis, IR spectra and single crystal X-ray diffraction. The 
molecular structure has a Zn(II) cation bound to two 
perpendicular bpt ligands in a distorted octahedral geometry 
through two sulfur and four nitrogen atoms. The crystal 
contains a disordered DMF solvate molecule. The cytotoxic 
activity measurement indicated that the complex exhibited 
superior antitumor activity against lung cancer A549 cell 
lines than the free ligand [179]. The ligand benzilbis(4-
methyl-3-thiosemicarbazone), MeNHCSNHN:CPhCPh: 
NNHCSNHMe (LH2) reacts with K2PtCl4 and Li2PdCl4forming  
cyclometalatedmesocates I (1, 4; M = Pt, Pd) and monomeric 
chelates II (2, 3; M = Pt, Pd), depending on the reaction 
conditions.  Complexation of K2PtCl4 both in the presence 
and absence of LiOH·H2O, yielded a mixture of 1 and 2 
(77:18) which could be easily separated by their different 
solubility. In contrast, reaction of Li2PdCl4 without base led 
to the formation of the monomeric [PdL] 3, while the use of 
LiOH·H2O permitted the selective synthesis of the 
cyclometalatedmesocate [Pd2(μ-L)2] (4). All the complexes 
were characterized by the usual techniques, including x-ray 
single crystal diffraction that showed all the complexes to be 
four-coordinate in a square-planar arrangement, but 2 and 3 
with a N2S2 environment while in 1 and 4 it was CNS2.  The 
cytotoxic activity has been evaluated against the human lung 
carcinoma cell line NCI-H460, but the results showed that the 
complexes were not vigorous against this cell line [180] 
Thiosemicarbazones and its copper complexes also cause 
membrane changes which is a characteristic of apoptosis 
[181].
 
 
Fig.8. Anticancer Activity targets of thiosemicarbazones 
 
2.7 Antimicrobial action of thiosemicarbazones and 
probable mechanisms-  
2.7.1 Antibacterial action 
The antibacterial agents usually act by disrupting bacterial 
growth or kill the bacteria without affecting the host. 
Antibacterial agents also inhibit the synthesis of 
peptidoglycan, change the microbial cytoplasmic membrane, 
alter translation and inhibit nucleic acid replication by 
blocking topoisomerases and transcription [182]. 
Antibacterial activity of Pt(II) and Pd(II) complexes of 2-
acetylpyridinethiosemicarbazone has been assessed against 
Staphylococcus aureus (S. aureus) and Escherichia coli (E. 
coli) [183]. Co(II) and Ni(II) complexes with 
benzilbisthiosemicarbazone have been tested against B. 
macerans and P. striata. Again in this case the metal 
complexes displayed better inhibitory effects than the 
parent ligand [184]. [Ag(mtsc)4] formed by the reaction of N-
morpholyl-2-acetylpyridine thiosemicarbazone and silver(I) 
contained Ag-O bond. The chloroform solution of the 
complex showed moderate activity against several bacterial 
strains but the complex did not show any activity in a water 
suspension system. The lack of activity can be attributed to 
low solubility or the high stability of the complex [185]. 
Antibacterial activity of salicaldehyde4-phenyl 
thiosemicarbazone, 2-hydroxy-1-naphthaldehyde 
thiosemicarbazone (Fig. 9) and 2-hydroxy-1-
naphthaldehyde 4-phenyl thiosemicarbazone complexes 
with Ru(II)-DMSO have been tested against several bacterial 
strains. The minimum inhibitory concentrations (MICs) of 
these complexes were greater when compared to standard 
as oxytetracyclin [186]. Literature has also revealed that the 
presence of some bulky groups at N4 position of the 
thiosemicarbazones can enhance the activity.  
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Fig. 9 2-hydroxy-1-naphthaldehyde thiosemicarbazone 
2.7.2Antiviral activity 
A series of isatin-β-thiosemicarbazones have been tested 
against herpes simplex virus type 1(HSV-1) and type 2 (HSV-
2). From the structure-activity relationship  confirmed the 
presence of thiourea group in thiosemicarbazone and the NH 
group in isatin were responsible for the activity of the 
compounds [187].  
2.7.3 Antimalarial activity 
Antimalarial activity of chimers of thiosmeicarbazones and 
ferroquine has been reported. The major contributor to the 
activity has been identified as 
aminoquinolinethiosemicarbazone[188]. Free ligand 3,4-
dichloroacetophenone thiosemicarbazone and its Pd(II) 
complex have been tested against P. falciparum strains 3D7 
(chloroquine sensitive) and K1(chloroquine and 
pyrimethamine resistant).  Pd complex  displayed  greater  
activity than the free ligand [189].  
2.7.4.Antitrypanosomal activity 
Glycolysis, an important biochemical metabolic pathway has 
been identified as a promising target for trypanosomal 
activity of drugs.  Sb(III) complexes of pyridine derived 
thiosemicarbazones have been tested against 
Trypanosomacruzi with better activity than the reference 
drugs benzimidazole and nifurtimox [190]. In vitro activity 
of Mn(II) complex obtained with N4-methyl-4-
nitrobenzaldehyde, N4-methyl-4nitroacetophenone and N4-
methyl-4-nitrobenzophenone thiosemicarbazones have been 
studied against T. cruzi [191].  
2.7.5. Antifungal activity 
The chelation theory can be used to study the  antifungal 
activity of the complex [192]. In some instances the 
increased lipophilicity causes the breakdown of the 
permeability barrier of the cell. Pt complexes with 2-
acetylpyridine thiosemicarbazone have shown effective 
antifungal activity towards yeast. Antifungicidal activity of 
heterocyclic thiosemicarbazone and their dimethylsilicone 
(IV) complexes has been demonstrated against several 
pathogenic fungi [193].  
 
Fig. 10. Bio activity spectrum of thiosemicarbazones 
3.0 Conclusion 
Schiff bases are important organic ligands having potential 
tendency of complexation with transition metals and they 
have shown excellent pharmacological properties over the 
years.  Thiosemicarbazones are well known Schiff based 
ligands which are usually neutral yet their anioninc forms 
are also known.  Their bidentate, tridentate or in some cases 
polydentate nature is due to the presence of donor atoms 
like sulphur, nitrogen or in some instances oxygen. As 
transition metals can exhibit an array of coordination power, 
they easily form stable complexes with Schiff based 
thiosemicarbazone ligands. Latest advances in medicinal 
inorganic chemistry have given considerable importance to 
the development of metal based drugs. Since the presence of 
metal ion in the drug moiety usually mitigates the ill effects 
of carbon-based compounds, this may lead to the production 
of new metal based drugs. The key factors identified for their 
action has been the inhibition of RR, topo II and the 
production of ROS, but identification of other probable 
targets need to be explored. The main action of the metal 
chelates when compared to free ligand is the prevalence of 
diffusive mechanism over the active transport mechanism 
across the membrane. The chelation of the metal ion by the 
polar regions of the ligands facilitates easy uptake by the 
cell. Just a limited number of in vivo studies have been done 
indicating the need of further deliberations. Attempts have 
been made to enhance the hydrophilicity and decrease the 
side effects of the parent moiety by suitable modifications in 
the thiosemicarbazone frameworks. Another area which 
needs attention is metal ion sequestering, as 
thiosemicarbazones are versatile chelators, they sometimes 
deprive the cell of essential metal ions by forming stable 
chelates with them. Lack of water solubility is another 
drawback of the compounds that needs to be work upon 
because it leads to lesser in vivo activity. Detailed studies are 
required to explore new mechanistic actions and the specific 
role of metal ions and ligand inside the body. Ligands which 
have poor or moderate activity should be studied in 
combination with ligands of good biological significance for 
activity enhancement. Interaction of one metal with another 
can also be explored taking synergistic effect into 
consideration. Not only this, the fact that needs exploration 
is whether the complex acts in unison or metal and ligand 
act independently inside the body needs a greater depth of 
understanding by interlinking chemistry and molecular 
biology. The redox capability of transition metals also is a 
key factor affecting the activity enhancement and structure 
modification in their structures to favour in vivo activity 
warrant future studies. 
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